STOCK TITAN

Imunon, Inc. - $IMNN STOCK NEWS

Welcome to our dedicated page for Imunon news (Ticker: $IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Imunon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Imunon's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Imunon, Inc.

Nasdaq:IMNN

IMNN Rankings

IMNN Stock Data

12.88M
9.37M
1.15%
4.47%
4.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LAWRENCEVILLE

About IMNN

celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.